vs
FONAR CORP（FONR）与迈心诺（MASI）财务数据对比。点击上方公司名可切换其他公司
迈心诺的季度营收约是FONAR CORP的14.5倍（$371.5M vs $25.5M）。FONAR CORP净利率更高（8.0% vs -27.0%，领先35.1%）。FONAR CORP同比增速更快（2.4% vs -26.4%）。迈心诺自由现金流更多（$50.9M vs $-227.0K）。过去两年FONAR CORP的营收复合增速更高（-0.3% vs -17.7%）
FONAR是一家专业医疗技术企业，专注于设计、制造及销售包括立式、开放式在内的创新磁共振成像（MRI）设备，主要服务美国的医院、影像诊断中心及医疗机构，为临床诊断提供高精度扫描解决方案。
迈心诺（Masimo Corporation）是总部位于美国加利福尼亚州尔湾的健康科技及消费电子企业，核心产品包括面向医院及家用场景的患者监护设备、无创传感器及配套软件平台，同时也布局了消费级音频和可穿戴设备赛道。
FONR vs MASI — 直观对比
营收规模更大
MASI
是对方的14.5倍
$25.5M
营收增速更快
FONR
高出28.8%
-26.4%
净利率更高
FONR
高出35.1%
-27.0%
自由现金流更多
MASI
多$51.1M
$-227.0K
两年增速更快
FONR
近两年复合增速
-17.7%
损益表 — Q2 2026 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $25.5M | $371.5M |
| 净利润 | $2.1M | $-100.4M |
| 毛利率 | — | 62.1% |
| 营业利润率 | 13.5% | 22.5% |
| 净利率 | 8.0% | -27.0% |
| 营收同比 | 2.4% | -26.4% |
| 净利润同比 | 4.7% | -1124.5% |
| 每股收益（稀释后） | — | $-1.84 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FONRMASI
| Q4 25 | $25.5M | — | ||
| Q3 25 | $26.0M | $371.5M | ||
| Q2 25 | $27.3M | $370.9M | ||
| Q1 25 | $27.2M | $372.0M | ||
| Q4 24 | $24.9M | $600.7M | ||
| Q3 24 | $25.0M | $504.6M | ||
| Q2 24 | $25.9M | $496.3M | ||
| Q1 24 | $25.7M | $492.8M |
净利润FONRMASI
| Q4 25 | $2.1M | — | ||
| Q3 25 | $2.3M | $-100.4M | ||
| Q2 25 | $729.3K | $51.3M | ||
| Q1 25 | $2.5M | $-170.7M | ||
| Q4 24 | $2.0M | $-349.6M | ||
| Q3 24 | $3.1M | $9.8M | ||
| Q2 24 | $830.4K | $16.0M | ||
| Q1 24 | $1.9M | $18.9M |
毛利率FONRMASI
| Q4 25 | — | — | ||
| Q3 25 | — | 62.1% | ||
| Q2 25 | — | 62.9% | ||
| Q1 25 | — | 62.9% | ||
| Q4 24 | — | 40.7% | ||
| Q3 24 | — | 52.2% | ||
| Q2 24 | — | 51.3% | ||
| Q1 24 | — | 49.0% |
营业利润率FONRMASI
| Q4 25 | 13.5% | — | ||
| Q3 25 | 14.1% | 22.5% | ||
| Q2 25 | 5.3% | 17.4% | ||
| Q1 25 | 15.2% | 21.0% | ||
| Q4 24 | 11.9% | -59.8% | ||
| Q3 24 | 21.0% | 6.0% | ||
| Q2 24 | 7.4% | 5.7% | ||
| Q1 24 | 16.8% | 6.9% |
净利率FONRMASI
| Q4 25 | 8.0% | — | ||
| Q3 25 | 8.7% | -27.0% | ||
| Q2 25 | 2.7% | 13.8% | ||
| Q1 25 | 9.2% | -45.9% | ||
| Q4 24 | 7.9% | -58.2% | ||
| Q3 24 | 12.6% | 1.9% | ||
| Q2 24 | 3.2% | 3.2% | ||
| Q1 24 | 7.3% | 3.8% |
每股收益（稀释后）FONRMASI
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.84 | ||
| Q2 25 | — | $0.94 | ||
| Q1 25 | — | $-3.12 | ||
| Q4 24 | — | $-6.54 | ||
| Q3 24 | — | $0.18 | ||
| Q2 24 | — | $0.29 | ||
| Q1 24 | — | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $121.0K | $312.3M |
| 总债务越低越好 | — | $559.1M |
| 股东权益账面价值 | $176.9M | $810.0M |
| 总资产 | $217.2M | $1.8B |
| 负债/权益比越低杠杆越低 | — | 0.69× |
8季度趋势，按日历期对齐
现金及短期投资FONRMASI
| Q4 25 | $121.0K | — | ||
| Q3 25 | $122.0K | $312.3M | ||
| Q2 25 | $56.5M | $149.6M | ||
| Q1 25 | $123.0K | $130.8M | ||
| Q4 24 | $121.0K | $177.6M | ||
| Q3 24 | $136.0K | $158.5M | ||
| Q2 24 | $56.5M | $129.6M | ||
| Q1 24 | $134.0K | $157.6M |
总债务FONRMASI
| Q4 25 | — | — | ||
| Q3 25 | — | $559.1M | ||
| Q2 25 | — | $613.7M | ||
| Q1 25 | — | $651.0M | ||
| Q4 24 | — | $765.2M | ||
| Q3 24 | — | $772.6M | ||
| Q2 24 | $66.9K | $781.6M | ||
| Q1 24 | — | $876.0M |
股东权益FONRMASI
| Q4 25 | $176.9M | — | ||
| Q3 25 | $174.9M | $810.0M | ||
| Q2 25 | $172.6M | $1.0B | ||
| Q1 25 | $171.9M | $946.4M | ||
| Q4 24 | $169.8M | $1.1B | ||
| Q3 24 | $168.7M | $1.5B | ||
| Q2 24 | $166.0M | $1.4B | ||
| Q1 24 | $165.8M | $1.4B |
总资产FONRMASI
| Q4 25 | $217.2M | — | ||
| Q3 25 | $218.4M | $1.8B | ||
| Q2 25 | $216.9M | $2.4B | ||
| Q1 25 | $214.9M | $2.3B | ||
| Q4 24 | $208.0M | $2.6B | ||
| Q3 24 | $212.3M | $3.1B | ||
| Q2 24 | $214.2M | $2.9B | ||
| Q1 24 | $209.6M | $3.0B |
负债/权益比FONRMASI
| Q4 25 | — | — | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.59× | ||
| Q1 25 | — | 0.69× | ||
| Q4 24 | — | 0.73× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | 0.00× | 0.57× | ||
| Q1 24 | — | 0.64× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $171.0K | $56.8M |
| 自由现金流经营现金流 - 资本支出 | $-227.0K | $50.9M |
| 自由现金流率自由现金流/营收 | -0.9% | 13.7% |
| 资本支出强度资本支出/营收 | 1.6% | 1.6% |
| 现金转化率经营现金流/净利润 | 0.08× | — |
| 过去12个月自由现金流最近4个季度 | $5.7M | $191.0M |
8季度趋势，按日历期对齐
经营现金流FONRMASI
| Q4 25 | $171.0K | — | ||
| Q3 25 | $1.7M | $56.8M | ||
| Q2 25 | $4.2M | $69.4M | ||
| Q1 25 | $3.1M | $31.1M | ||
| Q4 24 | $2.2M | $50.5M | ||
| Q3 24 | $1.7M | $25.6M | ||
| Q2 24 | $4.6M | $74.5M | ||
| Q1 24 | $2.8M | $45.8M |
自由现金流FONRMASI
| Q4 25 | $-227.0K | — | ||
| Q3 25 | $-177.0K | $50.9M | ||
| Q2 25 | $3.6M | $65.6M | ||
| Q1 25 | $2.6M | $28.5M | ||
| Q4 24 | $1.5M | $46.0M | ||
| Q3 24 | $-148.0K | $16.9M | ||
| Q2 24 | $4.2M | $66.9M | ||
| Q1 24 | $2.6M | $37.6M |
自由现金流率FONRMASI
| Q4 25 | -0.9% | — | ||
| Q3 25 | -0.7% | 13.7% | ||
| Q2 25 | 13.1% | 17.7% | ||
| Q1 25 | 9.4% | 7.7% | ||
| Q4 24 | 6.0% | 7.7% | ||
| Q3 24 | -0.6% | 3.3% | ||
| Q2 24 | 16.1% | 13.5% | ||
| Q1 24 | 10.2% | 7.6% |
资本支出强度FONRMASI
| Q4 25 | 1.6% | — | ||
| Q3 25 | 7.2% | 1.6% | ||
| Q2 25 | 2.4% | 1.0% | ||
| Q1 25 | 2.2% | 0.7% | ||
| Q4 24 | 3.0% | 0.7% | ||
| Q3 24 | 7.2% | 1.7% | ||
| Q2 24 | 1.6% | 1.5% | ||
| Q1 24 | 0.7% | 1.7% |
现金转化率FONRMASI
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.75× | — | ||
| Q2 25 | 5.79× | 1.35× | ||
| Q1 25 | 1.26× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 0.53× | 2.61× | ||
| Q2 24 | 5.54× | 4.66× | ||
| Q1 24 | 1.50× | 2.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
MASI
暂无分部数据
